文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

65岁以上梗阻性肥厚型心肌病室间隔减容术后的生存分析

Survival After Septal Reduction in Patients >65 Years Old With Obstructive Hypertrophic Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

该研究基于2013至2019年美国Medicare数据库,纳入5679例年龄>65岁接受室间隔减容术(SRT)的梗阻性肥厚型心肌病(oHCM)患者,比较室间隔心肌切除术(SM)与酒精室间隔消融术(ASA)的长期结局。调整混杂后,4年时两组全因死亡率无显著差异,但2年标志分析显示SM与更低死亡率相关,且SM组再次SRT需求更少;高手术量中心结局更优,但70%的SRT在低手术量中心完成。

要点

  • SRT可减少oHCM患者随访期心衰再入院。
  • SM较ASA与更低的再次SRT需求和2年后更优生存相关。
  • 高手术量中心结局更优,但多数手术在低手术量中心进行。

核心结论

  • 在Medicare的oHCM患者中,SRT减少了心衰再入院,SM较ASA与更低的再次SRT需求和更好的长期生存相关。
  • 尽管高手术量中心结局更好,但70%的SRT在美国低手术量中心完成。

研究设计与样本

  • 回顾性队列研究,纳入2013至2019年接受SRT(SM或ASA)的年龄>65岁Medicare受益人,共5679例(SM=3680,ASA=1999)。
  • 采用重叠倾向评分加权调整两组间差异,主要结局为全因死亡率,次要结局包括心衰再入院和随访期再次SRT需求。

主要发现

  • SM组平均年龄72.9岁、女性67.2%,ASA组平均年龄74.8岁、女性71.1%(P<0.01);SM组合并症较少,但调整后两组均衡。
  • 中位随访4年(IQR 2-6年)时,SM与ASA的长期死亡率无显著差异(HR 0.87;95%CI 0.74-1.03;P=0.1)。
  • 标志分析显示,随访2年后SM与更低的死亡率相关(HR 0.72;95%CI 0.60-0.87;P<0.001),且SM组再次SRT需求更低。
  • 与SRT前1年相比,两种SRT均减少了随访期心衰再入院。
  • 高手术量中心较短手术量中心结局更好,但70%的SRT在低手术量中心完成。

临床怎么用

  • 对于>65岁oHCM患者,SRT可减少心衰再入院,SM在减少再次SRT和2年后生存方面可能优于ASA。
  • 选择SRT术式时需权衡SM与ASA的长期结局差异,并考虑将患者转诊至手术量较高的中心以改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obstructive hypertrophic cardiomyopathy (oHCM) is increasingly being diagnosed in elderly patients. OBJECTIVES: The authors sought to study long-term outcomes of septal reduction therapies (SRT) in Medicare patients with oHCM, and hospital volume-outcome relation. METHODS: Medicare beneficiaries aged >65 years who underwent SRT, septal myectomy (SM) or alcohol septal ablation (ASA), from 2013 through 2019 were identified. Primary outcome was all-cause mortality, and secondary outcomes included heart failure (HF) readmission and need for redo SRT in follow-up. Overlap propensity score weighting was used to adjust for differences between both groups. Relation between hospital SRT volume and short-term and long-term mortality was studied. RESULTS: The study included 5,679 oHCM patients (SM = 3,680 and ASA = 1,999, mean age 72.9 vs 74.8 years, women 67.2% vs 71.1%; P < 0.01). SM patients had fewer comorbidities, but after adjustment, both groups were well balanced. At 4 years (IQR: 2-6 years), although there was no difference in long-term mortality between SM and ASA (HR: 0.87; 95% CI: 0.74-1.03; P = 0.1), on landmark analysis, SM was associated with lower mortality after 2 years of follow-up (HR: 0.72; 95% CI: 0.60-0.87; P < 0.001) and had lower need for redo SRT. Both reduced HF readmissions in follow-up vs 1 year pre-SRT. Higher-volume centers had better outcomes vs lower-volume centers, but 70% of SRT were performed in low-volume centers. CONCLUSIONS: SRT reduced HF readmission in Medicare patients with oHCM. SM is associated with lower redo and better long-term survival compared with ASA. Despite better outcomes in high-volume centers, 70% of SRT are performed in low-volume U.S. centers.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mentias A, Smedira NG, Krishnaswamy A, et al. Survival After Septal Reduction in Patients >65 Years Old With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2023. PMID: 36631204. doi:10.1016/j.jacc.2022.10.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。